Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, discusses results from a trial studying the combination of nivolumab and ibrutinib for the treatment of patients with relapsed non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, discusses results from a trial studying the combination of nivolumab (Keytruda) and ibrutinib (Imbruvica) for the treatment of patients with relapsed non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL).
Data was first seen with this combination in preclinical studies with mouse models of lymphomas and solid tumors. These exciting results have since been replicated in a number of trials. This trial specifically looked at subsets of patients with follicular lymphoma, diffuse large B-cell lymphoma, high-risk chronic lymphocytic leukemia, and Richter's transformation.
While the combination seems safe and can be administered in full doses within these subsets, the results from the Richter's transformation group stand out the most. The data in other subsets is no better or worse than in treatments with ibrutinib alone, but the Richter's transformation group displayed higher response rates with the combination than treatments with ibutinib as a single agent.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More